Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL819058 | 0.87 | PLA2G2A (0.61) | HTR6PLA2G2A | |
| Water SCHEMBL6975765 | 0.86 | PLA2G2A (0.60) | HTR6PLA2G2A | |
| SCHEMBL6694896 | 0.85 | PLA2G2A (0.59) | HTR6PLA2G2A | |
| SCHEMBL818539 | 0.84 | PLA2G2A (0.59) | HTR6PLA2G2A | |
| SCHEMBL29862561 | 0.84 | PLA2G2A (0.59) | HTR6PLA2G2A | |
| SCHEMBL6694894 | 0.84 | HTR6 (0.50) | HTR6PLA2G2A | |
| SCHEMBL6699402 | 0.83 | HTR6 (0.71) | HTR6PLA2G2A | |
| SCHEMBL6977940 | 0.79 | PLA2G2A (0.50) | HTR6PLA2G2A | |
| SCHEMBL29862413 | 0.79 | PLA2G2A (0.58) | HTR6PLA2G2A | |
| SCHEMBL817701 | 0.79 | PLA2G2A (0.58) | HTR6PLA2G2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040110825-A1 | Administration of an enzyme inhibitor of human non-pancreatic scretory phospholipase A2 (sPLA2) if activity levels are high or on the rise; treating within 0-24 hours after first organ failure and continuing as necessary, i.e., 1-7 days | LOH ANDREW (US) | 2004-06-10 | — | — | US | disclosed |
| EP-0839806-B1 | Substituted tricyclics | LILLY CO ELI (US) | 2003-07-09 | — | — | EP | disclosed |
| EP-1303262-A2 | USE OF A SPLA2 INHIBITOR FOR THE TREATMENT OF SEPSIS | ELI LILLY AND COMPANY (US) | 2003-04-23 | — | — | EP | disclosed |
| WO-2002005796-A2 | USE OF A SPLA2 INHIBITOR FOR THE TREATMENT OF SEPSIS | ELI LILLY AND COMPANY (US) | 2002-01-24 | — | — | WO | disclosed |
| WO-1998018464-A1 | SUBSTITUTED TRICYCLICS | ELI LILLY AND COMPANY (US) | 1998-05-07 | — | — | WO | disclosed |
| EP-0839806-A1 | Substituted tricyclics | ELI LILLY AND COMPANY (US) | 1998-05-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110825-A1 | Administration of an enzyme inhibitor of human non-pancreatic scretory phospholipase A2 (sPLA2) if activity levels are high or on the rise; treating within 0-24 hours after first organ failure and continuing as necessary, i.e., 1-7 days | PLA2G12A, PLA2G2E, PLA2G3 | HTR6 3251/4885PLA2G2A 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.